CN Patent

CN1809557B — 化合物

Assigned to AstraZeneca AB · Expires 2012-07-04 · 14y expired

What this patent protects

本发明涉及治疗增殖性疾病(如癌症)的式(I)的喹唑啉衍生物 及其在制备用于治疗增殖性疾病的药物中的用途，它们的制备方法，以及含有作为活性成分的所述化合物的药用组合物。

USPTO Abstract

本发明涉及治疗增殖性疾病(如癌症)的式(I)的喹唑啉衍生物 及其在制备用于治疗增殖性疾病的药物中的用途，它们的制备方法，以及含有作为活性成分的所述化合物的药用组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN1809557B
Jurisdiction
CN
Classification
—
Expires
2012-07-04
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.